Table 1 Compounds that increased potency when co-treated with ICRF193 were identified from the primary screening.

From: ICRF193 potentiates the genotoxicity of etoposide

Compound

Without ICRF193 IC50 (Efficacy)

With ICRF193 IC50 (Efficacy)

Trametinib

0.26 µM (92.3%)

0.021 µM (82.8%)

Mebendazole

20.59 µM (55.2%)

0.92 µM (61.9%)

Oxfendazole

14.58 µM (44.2%)

2.06 µM (49.7%)

Etoposide

29.08 µM (66.7%)

2.91 µM (99.1%)

Back to article page